持续的皮下与肠道Levodopa输液治疗帕金森病:一个现实世界,单心,观察性研究和批判性审查
Johannes Hartig1, Lennert Sitzmann1, Doreen Hartenstein1
1Department of Neurology, University Hospital Wuerzburg, Wuerzburg, Germany.
Movement disorders clinical practice
|February 12, 2026
概括
皮下利多巴-糖多巴 (SCFF) 在晚期帕金森病 (PD) 运动波动方面显示出现实有效性,但其学率高,患者和临床医生的分歧. 基于的疗法需要结构化的管理指南.
科学领域:
- 神经学 神经学
- 药理学 药理学 是一个学科.
- 医疗器械 医疗器械
背景情况:
- 晚期帕金森病 (PD) 在管理运动波动方面存在挑战.
- 皮下注射的利沃多巴-碳多巴 (SCFF) 输液是一种PD的新疗法.
- 与其他输液策略相比,关于SCFF有效性和不良事件的现实数据有限.
研究的目的:
- 为了提供关于SCFF输注的现实数据,用于高级PD.
- 为了比较SCFF的性能与肠道多巴胺治疗.
- 对PD的式疗法进行文献审查.
主要方法:
- 对晚期PD患者进行了回顾性单心研究.
- 与SCFF (n=58) 和levodopa-carbidopa肠凝 (n=70) 的比较.
- 提取真实世界的疗效和不良事件数据;系统的文献审查.
主要成果:
- 三分之一的SCFF患者在4周内退出,通常是由于偏好.
- 临床医生 (89%) 和患者 (74%) 的整体疗效印象有显著差异.
- 剂量调整和不良事件在疗法中很常见,但往往无法管理.
结论:
- 在控制PD电机波动方面,SCFF证明了现实世界的有效性.
- 显著的中断率,副作用和患者和临床医生的疗效分歧存在.
- 基于的PD疗法缺乏结构化的管理;建议使用指南和算法.
相关概念视频
Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34


